Compare SKE & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKE | ADMA |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.4B |
| IPO Year | 2017 | 2012 |
| Metric | SKE | ADMA |
|---|---|---|
| Price | $29.87 | $10.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 563.4K | ★ 4.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | $37,573.35 | $22.11 |
| P/E Ratio | ★ N/A | $17.37 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $11.37 | $7.21 |
| 52 Week High | $38.77 | $24.17 |
| Indicator | SKE | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 41.86 |
| Support Level | $27.50 | $7.21 |
| Resistance Level | $34.96 | $11.42 |
| Average True Range (ATR) | 1.26 | 0.44 |
| MACD | -0.40 | 0.15 |
| Stochastic Oscillator | 17.74 | 23.17 |
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.